Trinity Biotech (TRIB) announced that the in-country healthcare product regulatory authority has granted the approval to initiate offshore and outsourced manufacturing of its World Health Organization, WHO, prequalified TrinScreen HIV rapid test. This key approval now enables Trinity Biotech to transition upstream production from its legacy in-house operations to a more cost-effective and scalable outsourced model. Trinity Biotech has now begun manufacturing under this new model, marking a critical milestone in the Company’s transformation strategy.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech Gains Approval for PreClara™ Preeclampsia Testing Service
- Trinity Biotech receives approval from NYSDOH to provide PreClara Ratio
- Trinity Biotech Announces Breakthrough in CGM Technology
- Trinity Biotech announces clinical trial results for redesigned CGM sensor
- Trinity Biotech Launches FDA-cleared Preeclampsia Testing Service